ABSTRACT
Combined treatment of murine leukemia P388 with doxorubicin and platinum(IV)-nitroxyl complex ÐС118 administered in low doses improved efficiency of treatment (cure of 83% of animals) without increasing toxicity.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cytostatic Agents/pharmacology , Doxorubicin/pharmacology , Leukemia P388/drug therapy , Organoplatinum Compounds/pharmacology , Animals , Drug Administration Schedule , Leukemia P388/mortality , Leukemia P388/pathology , Longevity/drug effects , Mice , Mice, Inbred DBA , Survival AnalysisABSTRACT
In experimental animals with tumors it was studied antitumor activity of spirocyclic hydroxamic acids which could be classified as targeted agents as their target was enzyme histonedeacetylase, which was involved in the neoplastic process. The results showed that the hydroxamic acids were chemosensitizers for anticancer agents increasing their efficacy and enabling the researchers to reduce significantly the therapeutic dose. Also it was showed that hydroxamic acid, containing nitrogen mustard, was effective in the action on tumors with phenotype and genotype of multidrug resistance.
